![Frank Gleeson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Frank Gleeson
Fondatore presso SATELLOS BIOSCIENCE INC.
Patrimonio netto: 1 M $ in data 31/05/2024
Profilo
Frank Gleeson is the founder of Verio Therapeutics, Inc. (founded in 2008) and Satellos Bioscience, Inc. (founded in 2018).
At Satellos Bioscience, Inc., he holds the title of President, Chief Executive Officer & Director.
Mr. Gleeson is also the founder of Gleeson & Associates and the Canadian Glycomics Network.
Mr. Gleeson's former job positions include Chief Executive Officer at MDS Proteomics, Inc. from 1999 to 2003, Chairman at Stem Cell Network, Director at Privacy Analytics, Inc., and Senior Vice President at Mercal Capital Corp.
In terms of education, Mr. Gleeson attended York University and obtained an undergraduate degree as well as an MBA.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
SATELLOS BIOSCIENCE INC
3.38% | 16/05/2024 | 3 816 389 ( 3.38% ) | 1 M $ | 31/05/2024 |
Posizioni attive di Frank Gleeson
Società | Posizione | Inizio |
---|---|---|
SATELLOS BIOSCIENCE INC. | Fondatore | 01/01/2018 |
Gleeson & Associates | Fondatore | - |
Precedenti posizioni note di Frank Gleeson
Società | Posizione | Fine |
---|---|---|
MDS Proteomics, Inc. | Amministratore Delegato | 01/01/2003 |
Canadian Glycomics Network | Fondatore | - |
Verio Therapeutics, Inc.
![]() Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Fondatore | - |
Stem Cell Network | Presidente | - |
Satellos Bioscience, Inc. /Old/
![]() Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Amministratore Delegato | - |
Formazione di Frank Gleeson
York University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
SATELLOS BIOSCIENCE INC. | Health Technology |
Aziende private | 8 |
---|---|
MDS Proteomics, Inc. | Commercial Services |
Verio Therapeutics, Inc.
![]() Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Health Technology |
Privacy Analytics, Inc.
![]() Privacy Analytics, Inc. Packaged SoftwareTechnology Services Privacy Analytics, Inc. provides data anonymization software solutions for healthcare organizations, insurance and medical claims providers, and medical device manufacturers to safeguard and enable data for secondary purpose. The company was founded by Khaled El Emam in 2007 and is headquartered in Ottawa, Canada. | Technology Services |
Mercal Capital Corp.
![]() Mercal Capital Corp. Financial ConglomeratesFinance Mercal Capital Corp. is a capital pool company, which engages in the identification and evaluation of potential acquisitions or businesses. The company was founded on August 31, 2015 and is headquartered in Ottawa, Canada. | Finance |
Gleeson & Associates | |
Satellos Bioscience, Inc. /Old/
![]() Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
Stem Cell Network | |
Canadian Glycomics Network |
- Borsa valori
- Insiders
- Frank Gleeson